Top

 

References

  1. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolescent Psychiatry 1997;36: 1036–45.
  2. Nutt DJ, et al. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21(1): 10-41.
  3. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–1323.
  4. Castellanos FX, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288(14): 1740–1748.
  5. Valera EM, et al. Meta-analysis of structural imaging findings in attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007; 61(12): 1361–1369.
  6. Spencer TJ, et al. Overview and neurobiology of ADHD. J Clinical Psych 2002; 63(S12): 3-9.
  7. Gillberg C, et al. Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolescent Psychiatry 2004; 13(Suppl 1):I80-92.
  8. Concerta® XL Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/30451 [accessed August 2017].
  9. Equasym® XL. Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/15804 [accessed August 2017].
  10. Ritalin®. Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/1316 [accessed August 2017].
  11. Amfexa® 10mg. Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/32399 [accessed August 2017].
  12. Elvanse® (lisdexamfetamine). Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/27442 [accessed August 2017].
  13. Strattera®. Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/14482 [accessed August 2017].
  14. Kutcher S, et al. International consensus statement on attention deficit hyperactivity disorder (ADHD) and disruptive behaviour disorder: clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004; 14: 11-28.
  15. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006; 18(2): 155-172.
  16. Taylor E, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:17-30
  17. Thompson AE, et al. Children with ADHD transferring to secondary school: Potential difficulties and solutions. Clinical Child Psychology and Psychiatry 2003;8(1):91-103.
 

Top

ADHD-Mobile
Resource

Resources

Visit our resource centre for useful information and helpful activities for parents, teachers and teenagers living with ADHD.

Top

home_paralax_logo_320